‘Welcome back and welcome home’: ACC kicks off hybrid meeting with breaking CV science
Click Here to Manage Email Alerts
The 2022 American College of Cardiology Scientific Session will be held live in Washington, D.C., from April 2 to 4, and virtually, with 39 late-breaking trials and featured clinical research presentations.
‘Welcome back and welcome home’
“I am most excited about the fact that we are back to live education ... in the city that is the home of the ACC Heart House. So, welcome back and welcome home,” Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA, director of preventive cardiology, co-director of women’s heart care at the Medical University of South Carolina and chair of the 2022 ACC Scientific Session, said during a press conference held before the meeting. “This is the first year for a truly hybrid meeting, and I think you will find it is truly everything you have come to expect from the College and its flagship meeting and, in my opinion, even more.”
During the 3-day meeting, in-person and virtual attendees can join more than 200 education sessions, 11 learning pathways, eight guideline-specific sessions and six virtual channels.
“The pandemic has not slowed down the pace of science. It was very gratifying this year to see the number of abstract submissions,” Morris said during the press conference.
More than 5,300 abstracts were submitted for presentation at the session and 3,500 from 74 countries were accepted.
Five keynote presentations will also take place at the upcoming meeting:
- the Louis F. Bishop keynote with Dariush Mozaffarian, MD, FACC, on Saturday at noon EST: “Common Ground: What Do Heart Healthy Diets Have in Common”;
- the Douglas Zipes Distinguished Young Scientist keynote with Fatima Rodriguez, MD, MPH, FACC, on Saturday at noon EST, “Health Equity in Cardiovascular Disease Prevention”;
- the James T. Dove keynote with Valentin Fuster, MD, PhD, MACC, on Sunday at 2 p.m. EST: “Contemporary Consideration in Quality for Cardiovascular Research”;
- the Dan G. McNamara keynote with Daniel J. Penny, MD, FACC, on Monday at 11 a.m. EST: "Team Building and Innovation into the 21st Century”; and
- the Eugene Braunwald keynote with Peter Libby, MD, FACC, on Monday at 12:45 p.m. EST, “Inflammation Drives Atherosclerosis from Beginning to End.”
Late-breaking science
The meeting will feature 24 late-breaking clinical trials across five sessions and 15 featured clinical research presentations across three sessions.
Select late-breaking science scheduled to be presented at ACC includes:
- the VALOR-HCM trial, which assessed mavacamten (Bristol Myers Squibb) as an alternative to surgical septal myectomy or alcohol ablation for patients with severe symptomatic obstructive hypertrophic cardiomyopathy (HCM);
- the double-blind PACMAN AMI trial of the effects of alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis assessed by serial multimodality intracoronary imaging in patients with acute MI;
- the double-blind APOLLO trial of a short-interfering RNA-targeting lipoprotein(a);
- IVVE, a randomized trial to assess the effects of influenza vaccination on vascular events;
- the PROMPT-HF trial, which sought to improve use of guideline-directed medical therapies among outpatients with HF;
- updated results of treatment from the EXPLORER-LTE cohort of the MAVALTE study in patients with obstructive HCM;
- the 1-year results of the Clasp TR trial of transcatheter treatment of tricuspid regurgitation (Pascal, Edwards Lifesciences);
- the ADAPT-TAVR trial, which compared edoxaban (Savaysa, Daiichi Sankyo) with dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism following transcatheter aortic valve replacement;
- the FLAVOUR trial, which compared fractional flow reserve with IVUS-guided PCI for intermediate coronary artery stenosis; and
- the GIPS-IV trial, which tested the feasibility of sodium thiosulfate for the preservation of cardiac function after STEMI.
Other late-breaking trials to be presented include SODIUM-HF, POISE-3, MITIGATE, TRANSLATE-TIMI 70, SuperWIN, METEORIC-HF, DIAMOND, PROTECT, insights from the Corevalve U.S. Pivotal and SURTAVI trials, GHATI and BIO|GUARD-MI.
“These are all tremendously exciting studies among a host of others. ... I’ll briefly mention the PACIFIC-AF trial, APOLLO, CHOCOLATE TOUCH, METEORIC-HF, GHATI and NACMI studies, these are all ones that I think will have real opportunity to impact our practice as clinicians in the cardiovascular space,” Douglas E. Drachman, MD, FACC, Corrigan Minehan Heart Center director of education, Teresa G. and Ferdinand F. Martignetti Endowed Chair for cardiovascular medicine at Massachusetts General Hospital, vice chair of the 2022 Scientific Session, and future chair of the 2023 and 2024 Scientific Sessions, said during the press conference. “Not only will these studies be presented in the late-breaking clinical trials and featured clinical research sessions, but many will also be featured in the deep-dive sessions with investigators and expert discussants.”
Healio | Cardiology Today will be onsite in Washington, D.C. to report the latest news from the ACC Scientific Session, with physician perspective, researcher interviews and more. Follow our breaking updates here and by following @CardiologyToday on Twitter.
Collapse
Healio Coverage
Click Here to Manage Email Alerts